IGC Pharma, Inc.|4Jun 28, 1:46 PM ET

Moran James P 4

4 · IGC Pharma, Inc. · Filed Jun 28, 2023

Form 4

Period: 2023-03-31

Director

Transactions

Exercise/Conversion
Common Stock
2023-03-31+50,000→ 100,000 total
Exercise/Conversion
Restricted Stock Units
2023-03-31−33,334→ 66,666 total
→ Common Stock (33,334 underlying)
Award
Restricted Stock Units
2023-06-20+240,000→ 240,000 total
→ Common Stock (240,000 underlying)
Award
Restricted Stock Units
2022-05-25+100,000→ 100,000 total
→ Common Stock (100,000 underlying)
Exercise/Conversion
Restricted Stock Units
2023-03-31−50,000→ 50,000 total
→ Common Stock (50,000 underlying)
Award
Restricted Stock Units
2023-06-20+200,000→ 200,000 total
Exp: 2033-03-31→ Common Stock (200,000 underlying)
Exercise/Conversion
Common Stock
2023-03-31+33,334→ 133,334 total

Footnotes (5)

[F1]Represents 150,000 restricted shares of IGC common stock subject to vesting equally over three years starting on January 18, 2022, and then on March 31, 2023, and 2024, as per the RSU Agreement with Director Moran.
[F2]On May 25, 2022, the Reporting Person was granted RSUs subject to vesting equally over three years starting on March 31, 2023.
[F3]On June 20, 2023, the Reporting Person was granted RSUs subject to vesting equally over three years starting on March 31, 2024.
[F4]On June 20, 2023, the Reporting Person was granted RSUs subject to vesting according to specific milestones set by the Company's Board of Directors. The RSUs vest when milestones are achieved.
[F5]Each restricted stock unit represents a right to receive one share of IGC common stock.

Documents

1 file